Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Key Drivers
3.1.1. Surging Prevalence Of Chronic Disease
3.1.2. Advancements In Technology
3.1.3. Rising Approval Of Novel Oral Anticoagulants (Noacs)
3.2. Key Restraints
3.2.1. Side Effects Associated With Anticoagulants Treatment
3.2.2. High Price Of Noacs
3.2.3. Stringent Government Regulations

4. Key Analytics
4.1. Porter’S Five Forces Analysis
4.1.1. Threat Of New Entry
4.1.2. Threat Of Substitution
4.1.3. Buyer’S Power
4.1.4. Supplier’S Power
4.1.5. Competitive Rivalry
4.2. Impact Of Covid-19 On Anticoagulants Market
4.3. Opportunity Matrix
4.4. Vendor Landscape
4.5. Key Investment Insights

5. Market By Application
5.1. Atrial Fibrillation & Heart Attack
5.2. Pulmonary Embolism (Pe)
5.3. Deep Vein Thrombosis (Dvt)
5.4. Stroke
5.5. Other Applications

6. Market By Route Of Administration
6.1. Oral Anticoagulants
6.2. Injectable Anticoagulants

7. Market By Drug Class
7.1. Noacs
7.2. Heparins & Low-Molecular-Weight Heparins (Lmwhs)
7.3. Vitamin K Antagonists
7.4. Other Drug Class

8. Geographical Analysis
8.1. Europe
8.1.1. Market Size & Estimates
8.1.2. Key Growth Enablers
8.1.3. Key Challenges
8.1.4. Key Players
8.1.5. Country Analysis
8.1.5.1. Germany
8.1.5.2. France
8.1.5.3. United Kingdom
8.1.5.4. Italy
8.1.5.5. Russia
8.1.5.6. Belgium
8.1.5.7. Poland
8.1.5.8. Rest Of Europe

9. Competitive Landscape
9.1. Key Strategic Developments
9.1.1. Merger & Acquisitions
9.1.2. Product Launch & Developments
9.1.3. Partnership, Contract/Agreement & Collaboration
9.1.4. Business Expansion/ Approval/ Announcement
9.2. Company Profile
9.2.1. Abbott Laboratories
9.2.2. Alexion Pharmaceutical Inc
9.2.3. Aspen Pharmacare Holdings Limited
9.2.4. Bayer Ag
9.2.5. Boehringer Ingelheim Gmbh
9.2.6. Bristol-Myers Squibb Company
9.2.7. Daiichi Sankyo
9.2.8. Dr. Reddy’S Laboratories
9.2.9. Glaxosmithkline Plc
9.2.10. Johnson & Johnson
9.2.11. Leo Pharma As
9.2.12. Merck & Co.
9.2.13. Novartis Ag
9.2.14. Pfizer Inc
9.2.15. Sanofi



List of Figures


List of Figures

:
Figure 1: Porter’S Five Force Analysis
Figure 2: Opportunity Matrix
Figure 3: Vendor Landscape
Figure 4: Key Investment Insights
Figure 5: Europe Anticoagulants Market, By Application, In 2020
Figure 6: Europe Anticoagulants Market, By Atrial Fibrillation & Heart Attack, 2021-2028 (In $ Million)
Figure 7: Europe Anticoagulants Market, By Pulmonary Embolism (Pe), 2021-2028 (In $ Million)
Figure 8: Europe Anticoagulants Market, By Deep Vein Thrombosis (Dvt), 2021-2028 (In $ Million)
Figure 9: Europe Anticoagulants Market, By Stroke, 2021-2028 (In $ Million)
Figure 10: Europe Anticoagulants Market, By Other Applications, 2021-2028 (In $ Million)
Figure 11: Europe Anticoagulants Market, By Route Of Administration, In 2020
Figure 12: Europe Anticoagulants Market, By Oral Anticoagulants, 2021-2028 (In $ Million)
Figure 13: Europe Anticoagulants Market, By Injectable Anticoagulants, 2021-2028 (In $ Million)
Figure 14: Europe Anticoagulants Market, By Drug Class, In 2020
Figure 15: Europe Anticoagulants Market, By Noacs, 2021-2028 (In $ Million)
Figure 16: Europe Anticoagulants Market, By Heparins & Low-Molecular-Weight Heparins (Lmwhs), 2021-2028 (In $ Million)
Figure 17: Europe Anticoagulants Market, By Vitamin K Antagonists, 2021-2028 (In $ Million)
Figure 18: Europe Anticoagulants Market, By Other Drug Class, 2021-2028 (In $ Million)
Figure 19: Europe Anticoagulants Market, Country Outlook, 2020 & 2028 (In %)
Figure 20: Germany Anticoagulants Market, 2021-2028 (In $ Million)
Figure 21: France Anticoagulants Market, 2021-2028 (In $ Million)
Figure 22: United Kingdom Anticoagulants Market, 2021-2028 (In $ Million)
Figure 23: Italy Anticoagulants Market, 2021-2028 (In $ Million)
Figure 24: Russia Anticoagulants Market, 2021-2028 (In $ Million)
Figure 25: Belgium Anticoagulants Market, 2021-2028 (In $ Million)
Figure 26: Poland Anticoagulants Market, 2021-2028 (In $ Million)
Figure 27: Rest Of Europe Anticoagulants Market, 2021-2028 (In $ Million)


List of Tables


List of Tables


TABLE 1: MARKET SNAPSHOT - ANTICOAGULANTS
TABLE 2: EUROPE ANTICOAGULANTS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 3: EUROPE ANTICOAGULANTS MARKET, BY APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 4: EUROPE ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 5: EUROPE ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 6: EUROPE ANTICOAGULANTS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 7: EUROPE ANTICOAGULANTS MARKET, BY DRUG CLASS, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 8: EUROPE ANTICOAGULANTS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 9: EUROPE ANTICOAGULANTS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 10: LEADING PLAYERS OPERATING IN EUROPE ANTICOAGULANTS MARKET